Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?

5,222 shares were sold on June 8, 2026 for a transaction value of approximately $143,000 at a weighted average price around $27.30 per share. The transaction represented 3.60% of Mark Schoenberg's direct holdings, reducing his position from 144,985 to 139,763 shares.

The Motley Fool • Jun 14, 2026

UroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

UroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 10, 2026

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

GlobeNewsWire • Jun 5, 2026

UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution

Agreement reinforces the value of UroGen's innovation and reflects the strength of the Company's intellectual property portfolio Teva will be granted a non-exclusive license to sell its generic version of JELMYTO beginning on September 15, 2030, if approved by the FDA PRINCETON, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

GlobeNewsWire • Jun 2, 2026

UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

PRINCETON, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference to take place on June 8-10, 2026.

GlobeNewsWire • Jun 1, 2026

UroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent Bladder Cancer Transcript

UroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent Bladder Cancer Transcript

Seeking Alpha • May 17, 2026

UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC

PRINCETON, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

GlobeNewsWire • May 15, 2026

UroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

UroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 13, 2026

ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial

64.5% Probability of Remaining Event-Free at Three Years by Kaplan-Meier Analysis After Achieving Complete Response at Three Months First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

GlobeNewsWire • May 13, 2026

Urogen Pharma (URGN) Just Flashed Golden Cross Signal: Do You Buy?

From a technical perspective, Urogen Pharma (URGN) is looking like an interesting pick, as it just reached a key level of support. URGN's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.

Zacks Investment Research • May 11, 2026